Foghorn Raises $50M, Extends Runway to 2028 and Advances FHD-909 Trial
Foghorn’s FHD-909 Phase 1 dose-escalation for SMARCA4-mutant NSCLC is progressing on schedule with preclinical data showing enhanced anti-tumor activity in combination with pembrolizumab and KRAS inhibitors. A $50 million registered direct financing boosts year-end cash to $158.9 million, extending runway into H1 2028 while CBP and EP300 degrader programs track to 2026 IND studies.
1. Lead Candidate FHD-909 Advancement
FHD-909 (LY4050784) is progressing through Phase 1 dose escalation in SMARCA4-mutant NSCLC, with the first patient dosed in October 2024. Preclinical models demonstrate synergistic anti-tumor effects when combined with pembrolizumab and novel KRAS inhibitors, supporting planned front-line combination studies pending dose escalation results.
2. Progress on Selective Degrader Programs
The Selective CBP degrader CBPd-171 has shown potent efficacy in ER+ breast cancer models without impacting platelet counts and is undergoing dose-range finding toxicology studies, with IND-enabling studies expected in 2026. The Selective EP300 degrader targets hematologic malignancies like DLBCL and multiple myeloma, also tracking to IND readiness in 2026.
3. Financial Update and Corporate Strength
In January 2026, Foghorn closed a $50 million registered direct financing at $6.71 per share, lifting year-end cash, cash equivalents and marketable securities to $158.9 million and extending the cash runway into the first half of 2028. In February 2026, Ryan Maynard joined as CFO, bringing over 25 years of biopharma finance and capital markets experience.